4 Einträge gefunden

1. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

   1. Landgren, Ola
   2. Weisel, Katja
   3. Rosinol, Laura
   4. Touzeau, Cyrille
   5. Turgut, Mehmet
   6. Hajek, Roman
   7. Mollee, Peter

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

   1. Ludwig, Heinz
   2. Pönisch, Wolfram
   3. Knop, Stefan
   4. Egle, Alexander
   5. Hinke, Axel
   6. Schreder, Martin
   7. Lechner, Daniel

   2020 - Forschungsinformationssystem des UKE
3. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

   1. Dimopoulos, Meletios A
   2. Niesvizky, Ruben
   3. Weisel, Katja
   4. Siegel, David S
   5. Hajek, Roman
   6. Mateos, María-Victoria
   7. Cavo, Michele

   2020 - Forschungsinformationssystem des UKE
4. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

   1. Ludwig, Heinz
   2. Poenisch, Wolfram
   3. Knop, Stefan
   4. Egle, Alexander
   5. Schreder, Martin
   6. Lechner, Daniel
   7. Hajek, Roman

   2019 - Forschungsinformationssystem des UKE